Last reviewed · How we verify

NCT05406947

Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children

Not yet recruiting Last updated 8 February 2023
What this trial tests

trial testing Prospective observational study, no intervention in Medulloblastoma, Childhood in 350 participants. Not yet recruiting.

Timeline
30 January 2023
Primary endpoint
31 December 2028
31 December 2030

Quick facts

Lead sponsorBeijing Tiantan Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment350
Start date30 January 2023
Primary completion31 December 2028
Estimated completion31 December 2030

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 6 Months to 18, any sex, with Medulloblastoma, Childhood. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Medulloblastoma, Childhood

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05406947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing